PRINCETON, N.J. & SEATTLE--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and ZymoGenetics, Inc. (NASDAQ:ZGEN) announced that final results from a Phase 1b clinical trial in patients with hepatitis C (HCV) treated with PEG-Interferon lambda, a new class of interferon, in combination with ribavirin will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting October 30–November 3, 2009, in Boston.
